Add to ORKGThe value of vasodilator therapy in acute and chronic heart failure is well established. Vasodilators improve symptoms and prognosis in patients with severe clinical symptoms refractory to the treatment with diuretics and digitalis. Angiotensin-converting enzyme (ACE) inhibitors were beneficial even in less severe heart failure. Most recent studies suggest that prevention of heart failure is possible in patients with severe left ventricular dysfunction
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
AbstractDuring the past 10 years, more than 80 orally active vasodilator and inotropic agents have b...
Over the past decade, several trials have questioned the efficacy of vasodilator therapy in acute he...
The current status of the use of vasodilator drugs in the treatment of acute and chronic heart failu...
Agents with vasodilator properties (AVDs) are frequently used in the treatment of acute heart failur...
Oral vasodilators have proved to be valuable drugs in the management of systolic or diastolic conges...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
Although substantial progress has been made in the last 5 years in the development of vasodilator an...
Vasodilators currently prescribed in the treatment of congestive heart failure represent a wide clas...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
AbstractVasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 year...
In the past 50 years, an increased understanding of the pathophysiologic mechanisms associated with ...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
The clinical diagnosis of heart failure is independent of aetiology. Treatment strategies are aimed ...
AbstractVasodilator therapy is useful adjunctive therapy in the management of both acute and chronic...
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
AbstractDuring the past 10 years, more than 80 orally active vasodilator and inotropic agents have b...
Over the past decade, several trials have questioned the efficacy of vasodilator therapy in acute he...
The current status of the use of vasodilator drugs in the treatment of acute and chronic heart failu...
Agents with vasodilator properties (AVDs) are frequently used in the treatment of acute heart failur...
Oral vasodilators have proved to be valuable drugs in the management of systolic or diastolic conges...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
Although substantial progress has been made in the last 5 years in the development of vasodilator an...
Vasodilators currently prescribed in the treatment of congestive heart failure represent a wide clas...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
AbstractVasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 year...
In the past 50 years, an increased understanding of the pathophysiologic mechanisms associated with ...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
The clinical diagnosis of heart failure is independent of aetiology. Treatment strategies are aimed ...
AbstractVasodilator therapy is useful adjunctive therapy in the management of both acute and chronic...
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
AbstractDuring the past 10 years, more than 80 orally active vasodilator and inotropic agents have b...
Over the past decade, several trials have questioned the efficacy of vasodilator therapy in acute he...